Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACC085 SAD in Healthy Chinese Adults
NCT07835633Phase 1Recruiting
- Sponsor
- Aidea Pharma
- Start
- Aug 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ACC085 in human immunodeficiency virus infection (HIV) (5 arms), sponsored by Aidea Pharma. Primary endpoint: Incidence and Severity of Adverse Events at 48 weeks. Started Aug 2026; status: recruiting.
02
Drugs
ACC085
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07835633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07835633.